Cabozantinib (Cabometyx®) in combination with nivolumab (Opdivo®). HTA ID: 22018

Assessment Status Rapid Review complete
HTA ID 22018
Drug Cabozantinib/Nivolumab
Brand Cabometyx®/Opdivo®
Indication First-line treatment of advanced renal cell carcinoma in adults.
Assessment Process
Rapid review commissioned 28/03/2022
Rapid review completed 11/05/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cabozantinib (Cabometyx®) in combination with nivolumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.